enhancing vision to revitalize life...the eyedaptic solution … effective full field of vision …...
TRANSCRIPT
Copyright Eyedaptic, Inc., © 2018 all rights reserved
Enhancing Vision to Revitalize Life
contact: Jay Cormier
1-978-809-0678
2
The Eyedaptic Solution
… effective full field of
vision
… wearable for mobility
… AR seamless
integration
… easy to use & visually adaptive
3
We simulate natural vision to
help people return to fuller
lives
U.S. FDA Class I Exempt Device
Magnification Alone is Inadequate
It Drastically DiminishesField of Vision
Market Landscape
NO Available Treatment for Dry AMD (90% of cases)
4
Intermediate &
Late Stage AMD
60M worldwide
178M AMD sufferers worldwide
400M with retinal disease worldwide
How Our Solution Works
Simulated NaturalVision
Visionw/AMD
Open Market AR Hardware+ Proprietary Software 1
ImageCapture
Display
1. 9 Patents pending & FTO completed
5
Adaptive Systems 1
Key Opinion Leaders
Technology validated
improved reading
&
everyday tasks easier
Technology Validation & Clinical Trials
6
>50 Users to Date
73 – 105 Age Range
20/60 – 20/400 Vision
Mostly Dry AMD
Improved 35% - 50%
Clinical Trial: Validation of Features
Assessment of ability to perform a given task with and without EYE-01
Timed Independent Activities of Daily Living (TIADLs):▪ Reading a bill▪ Identify & Read Cans▪ Sign spotting & reading
0
5
10
15
20
Bill Can Signs
Successful Task Completion (N=20)
Without EYE-01 With Eye-01
Over 5XImprovement
Clinical Trial: Vision Improvement
Quantitative Evaluation of reading ability and visual acuity
MNRead Reading Assessment:▪ Critical print size▪ Reading Acuity▪ Scotoma pattern
dependencies 0
5
10
15
20
25
30
35
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Change from Baseline (letters gained)
Letters Gained (N=20) Average EYE-01 (N=20)
Average Lucentis Average Eyelea
> 100% Improvement vs. Baseline
Improved from 20/125 → 20/60
User Data: In Home Usage across a variety of users & tasks
> 500 Hours of Usage
0
20
40
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
# Sessions
0
5
10
15
20
25
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Time
Market Entry Strategy
Retinal MDs
10
Late StageMacular
Degeneration
Premier Model & Full SW
IntermediateStage
MacularDegeneration
Basic Model & Core SW
GeneralOptometry
Low VisionCenters
Jay CormierPresident & CEO Founder
Dave WatolaChief Tech Officer Cofounder
Dr. Mitul MehtaChief Medical Officer Cofounder
Dr. Brian KimMedical Advisor Cofounder
Jerry FitchBoard Director
Art ReidelBoard Director
Peter Gluck Esq.IP Advisor
Dr. B. KuppermannRetina Advisor
Dr. Becky KammerLow Vision Advisor
Brian SchleigerEye Care / Low VisionSales Manager
Lou LipschultzEye Care / Low Vision Commercial Advisor
11
Dr. Paul KarpeckiOptometry Advisor
Team
Technology Medical
Key Milestones
Completed 2018 2020Completed 2019
Core Tech Validated
Patents Filed
BetaLaunch
Clinical
Trial
>500hours
Core SW& Features
PilotLaunch
USALaunch
PremierProduct
Copyright Eyedaptic, Inc., © 2018 all rights reserved
contact: Jay Cormier
1-978-809-0678